181 related articles for article (PubMed ID: 35212920)
1. Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma.
de Sousa LG; Neto FL; Lin J; Ferrarotto R
Curr Oncol Rep; 2022 May; 24(5):621-631. PubMed ID: 35212920
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments.
de Sousa LG; Jovanovic K; Ferrarotto R
Curr Treat Options Oncol; 2022 Aug; 23(8):1135-1150. PubMed ID: 35854180
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
[TBL] [Abstract][Full Text] [Related]
4. Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma.
Lorini L; Ardighieri L; Bozzola A; Romani C; Bignotti E; Buglione M; Guerini A; Lombardi D; Deganello A; Tomasoni M; Bonini SA; Sigala S; Farina D; Ravanelli M; Bossi P
Oral Oncol; 2021 Apr; 115():105213. PubMed ID: 33578204
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
6. Approaches to the Management of Metastatic Adenoid Cystic Carcinoma.
Lee RH; Wai KC; Chan JW; Ha PK; Kang H
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428790
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Immunotherapy and Clinical Utility of Comprehensive Genomic Profiling in Adenoid Cystic Carcinoma of Head and Neck.
Naito T; Noji R; Kugimoto T; Kuroshima T; Tomioka H; Fujiwara S; Suenaga M; Harada H; Kano Y
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138214
[No Abstract] [Full Text] [Related]
8. Systemic and Targeted Therapies in Adenoid Cystic Carcinoma.
Kacew AJ; Hanna GJ
Curr Treat Options Oncol; 2023 Jan; 24(1):45-60. PubMed ID: 36637743
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ
Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857
[TBL] [Abstract][Full Text] [Related]
10. Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel.
Fukuda N; Fujiwara Y; Wang X; Ohmoto A; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Takahashi S
Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3037-3043. PubMed ID: 33219858
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma.
Hanna GJ; Bae JE; Lorch JH; Schoenfeld JD; Margalit DN; Tishler RB; Haddad RI; Chau NG
Oral Oncol; 2020 Jul; 106():104690. PubMed ID: 32283496
[TBL] [Abstract][Full Text] [Related]
12. [The clinicopathological features and curative effect of the bronchoscopic interventional therapy combined with radiotherapy for the treatment of locally recurrent lung adenoid cystic carcinoma].
Zhu DC; Xu JH; Zhang MH; Zhu HX; Zhang Y; Zhang T; Xu GR
Zhonghua Zhong Liu Za Zhi; 2018 Nov; 40(11):864-868. PubMed ID: 30481940
[No Abstract] [Full Text] [Related]
13. A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma.
Hanna GJ; ONeill A; Cutler JM; Flynn M; Vijaykumar T; Clark JR; Wirth LJ; Lorch JH; Park JC; Mito JK; Lohr JG; Kaufman J; Burr NS; Zon LI; Haddad RI
Oral Oncol; 2021 Aug; 119():105366. PubMed ID: 34091189
[TBL] [Abstract][Full Text] [Related]
14. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors.
Sousa LG; McGrail DJ; Lazar Neto F; Li K; Marques-Piubelli ML; Ferri-Borgogno S; Dai H; Mitani Y; Spardy Burr N; Cooper ZA; Kinneer K; Cortez MA; Lin SY; Bell D; El Naggar A; Burks J; Ferrarotto R
Clin Cancer Res; 2023 Aug; 29(16):3162-3171. PubMed ID: 37256648
[TBL] [Abstract][Full Text] [Related]
15. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling.
Ferrarotto R; Mishra V; Herz E; Yaacov A; Solomon O; Rauch R; Mondshine A; Motin M; Leibovich-Rivkin T; Davis M; Kaye J; Weber CR; Shen L; Pearson AT; Rosenberg AJ; Chen X; Singh A; Aster JC; Agrawal N; Izumchenko E
Cell Death Dis; 2022 Aug; 13(8):678. PubMed ID: 35931701
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.
Dillon PM; Petroni GR; Horton BJ; Moskaluk CA; Fracasso PM; Douvas MG; Varhegyi N; Zaja-Milatovic S; Thomas CY
Clin Cancer Res; 2017 Aug; 23(15):4138-4145. PubMed ID: 28377480
[No Abstract] [Full Text] [Related]
17. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.
Ho AS; Ochoa A; Jayakumaran G; Zehir A; Valero Mayor C; Tepe J; Makarov V; Dalin MG; He J; Bailey M; Montesion M; Ross JS; Miller VA; Chan L; Ganly I; Dogan S; Katabi N; Tsipouras P; Ha P; Agrawal N; Solit DB; Futreal PA; El Naggar AK; Reis-Filho JS; Weigelt B; Ho AL; Schultz N; Chan TA; Morris LG
J Clin Invest; 2019 Oct; 129(10):4276-4289. PubMed ID: 31483290
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of gefitinib in patients with advanced salivary gland cancers.
Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: a preclinical study.
Savarese T; Abate A; Basnet RM; Lorini L; Gurizzan C; Tomasoni M; Lombardi D; Tomasini D; Zizioli D; Memo M; Berruti A; Bonini SA; Sigala S; Bossi P
Sci Rep; 2022 Jun; 12(1):9951. PubMed ID: 35705678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
